Pharmaceutical Patent AnalystVol. 7, No. 5 CommentaryThree years on from Teva, where are we now?Kenneth R Adamo, Eugene Goryunov, Ryan M Hubbard & Sarah M CraigKenneth R Adamo Kirkland & Ellis LLP, 300 North LaSalle, Chicago, IL 60654, USASearch for more papers by this author, Eugene Goryunov*Author for correspondence: E-mail Address: egoryunov@kirkland.com Kirkland & Ellis LLP, 300 North LaSalle, Chicago, IL 60654, USASearch for more papers by this author, Ryan M Hubbard Kirkland & Ellis LLP, 300 North LaSalle, Chicago, IL 60654, USASearch for more papers by this author & Sarah M Craig Kirkland & Ellis LLP, 300 North LaSalle, Chicago, IL 60654, USASearch for more papers by this authorPublished Online:1 Aug 2018https://doi.org/10.4155/ppa-2018-0013AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleReferences1 Teva Pharm. USA, Inc. v. Sandoz, Inc., 135 S. Ct. 831 (2015).Google Scholar2 Teva Pharm. USA, Inc. v. Sandoz, Inc., 789 F.3d 1335 (Fed. Cir. 2015).Google Scholar3 Shire Dev., LLC v. Watson Pharm., Inc., 787 F.3d 1359 (Fed. Cir. 2015).Google Scholar4 Dow Chemical v. NOVA Chemicals Corp., 803 F.3d 620 (2015).Google Scholar5 Eli Lilly & Co. v. Teva Parenteral Meds., Inc., 845 F.3d 1357 (Fed. Cir. 2017).Google Scholar6 Aptalis Pharmatech, Inc. v. Apotex, Inc., No. 2017-1344, 2018 WL 286123 (Fed. Cir. Jan. 4, 2018).Google Scholar7 Sumitomo Dainippon Pharma Co. v. Emcure Pharm. Ltd, No. 2017-1798, -1799, -1800, 2018 WL 1787667 (Fed. Cir. Apr. 16, 2018).Google ScholarFiguresReferencesRelatedDetails Vol. 7, No. 5 Follow us on social media for the latest updates Metrics Downloaded 36 times History Received 24 April 2018 Accepted 27 June 2018 Published online 1 August 2018 Published in print September 2018 Information© 2018 Newlands PressDisclaimerThis article reflects only the present considerations and views of the authors, which should not be attributed to Kirkland & Ellis, or to any of its or their former or present clients.Financial & competing interests disclosureAll authors are employees of Kirkland & Ellis LLP. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download